Main Page Content

TORONTO (Aug. 25, 2020) – An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.

For patients undergoing percutaneous coronary intervention (PCI) – a non-surgical procedure where physicians inflate a balloon and place a metal stent in narrowed heart arteries to improve blood flow to the heart – the choice of antiplatelet therapy can be critical to post-treatment success, and to minimize the chance of heart attack or stroke. 

The TAILOR-PCI trial, co-led by principal investigators Dr. Michael Farkouh, cardiologist and Multinational Clinical Trials Chair at UHN's Peter Munk Cardiac Centre, and Dr. Naveen Pereira, Professor of Medicine and cardiologist at Mayo Clinic, studied the effectiveness of genetic-guided therapy in patients that have had PCIs when compared to conventional therapy.

"The trial introduces the concept and validates the approach to personalized medicine when it comes to antiplatelet therapy, and therefore allows our physicians to potentially change their practice based on the needs of patients undergoing PCI," says Dr. Farkouh. "This will potentially inform the kinds of therapies patients with heart disease are prescribed after PCI worldwide."

Placement of a balloon and metal stent inside a heart artery can irritate the blood vessel and cause it to clot, which can block the artery from being treated. PCI patients are prescribed medications to prevent their blood from clotting – the most common medication used is clopidogrel, which stops blood platelets from sticking together and prevents clots from forming. However, in almost a third of all patients, the gene (CYP2C19) required to activate clopidogrel does not work.

As a result, patients with this genetic variant may be at a higher risk of experiencing adverse cardiovascular events, such as heart attack or stroke in the year following their procedure.

Current guidelines do not recommend genetic testing when prescribing clopidogrel, and the trial was designed to determine if genetic testing would decrease cardiovascular complications after PCI.

The Journal of the American Medical Association published the results of the TAILOR-PCI trial on Aug. 25.The trial enrolled 5,302 patients treated for heart artery blockage with one or more stents, and followed them for one year.

Half the group was tested for the CYP2C19 gene variation, and carriers (35 per cent) were treated with the alternative anti-platelet medication, ticagrelor. The remainder of the group was given clopidogrel, as was the entire control group of patients who did not receive genetic testing before PCI.

Although the TAILOR-PCI trial did not meet its primary endpoint of demonstrating a 50 per cent reduction at one-year post-procedure, trends did show a benefit towards genetic testing with a 34 per cent reduction in serious adverse cardiovascular events.

"Although these results fell short of the effect size that we predicted, they nevertheless provide a signal that offers support for the benefit of genetically guided therapy, with approximately one-third fewer adverse events in the patients who received genetically-guided treatment compared with those who did not," says Dr. Pereira.

A post-hoc analysis of the trial also showed a nearly 80 per cent reduction in the rate of adverse events in the first three months of treatment among patients who received genetically-guided therapy compared with those who did not.

Since the study's design in 2012, the standard of care following PCIs has greatly improved. Drug-coated stents and other treatments have reduced the rate of adverse events for patients in a year, but at the same time made it more difficult for the trial to reach its goal.

The trial is currently undergoing an extended follow-up beyond the original 12-month period.

The study was funded by Mayo Clinic, Mayo Clinic Center for Individualized Medicine and the National Heart, Lung and Blood Institute. Spartan Bioscience Inc. supplied the point-of-care genetic tests used.

For more information, or to book an interview with Dr. Farkouh, please contact:

Rosa Kim
Senior Public Affairs Advisor
University Health Network - Toronto General Hospital and Peter Munk Cardiac Centre
Phone: 416 340 3895
M: 647 669 8416
Email: rosa.kim@uhn.ca

About the Peter Munk Cardiac Centre:

The Peter Munk Cardiac Centre, established through the generous support of The Peter and Melanie Munk Charitable Foundation, is the premier cardiac centre in Canada. Each year, over 163,000 patients receive innovative and compassionate care from a multidisciplinary team who treat some of the most complex cases of heart and vascular disease. Our clinical and research expertise has improved the lives of patients around the world, while we continue to train more cardiologists, cardiovascular surgeons, and vascular surgeons than any other hospital in Canada. The Peter Munk Cardiac Centre is based at Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute – all members of University Health Network. For more information, visit www.petermunkcardiaccentre.ca


Share This Story

Share Tweet Email